Comorbidities and associated factors in patients with alopecia areata
Keywords:
alopecia areata, comorbidities, risk factors, secondary health care.Abstract
Introduction: The alopecia areata in an autoimmune disease characterized by the non-cicatricial loss of hair; that can be classified as a cosmetic problem, without taking into account that has high impact in the life quality of the one who suffers from the disease.
Objective: To identify the comorbidities, psychosocial impact and associated factors in patients with alopecia areata.
Methods: An observational, descriptive and cross-sectional study of 50 patients with clinical diagnosis of alopecia areata was carried out, they were assisted in Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba, from 2018 to 2020.
Results: In the case material there was a prevalence of the 29-39 years patients (46.0 %), the male sex (58.0 %), stress and anxiety as emotional factors (76.0 %), followed by the septic focus (40.0 %); the school level of technician (52.0 %), accompanied as marital status (44.0 %) and the time of evolution of the alopecia between 4 and 12 months (76.0 %).
Conclusions: It was evidenced that most of the patients presented some emotional event or a crisis of anxiety before the beginning of the alopecia areata.
Downloads
References
2. Manzur katrib J, Díaz Almeida JG, Cortés Hernández M, Ortiz González PR, Sagaró Delgado B, Abreu Daniel A, et al. Dermatología. La Habana: Editorial Ciencias Médicas; 2002. p. 1 – 22.
3. Lee S, Lee YB, Kim BJ, Lee WS. Screening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 [citado 11/10/2022];80(5):1410-3. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0190962218328883
4. Strazzulla LC, Chun Wang EH, Avila L, Sicco KL, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018 [citado 11/10/2021];78(1):1-12. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S019096221731873X
5. Dainichi T, Kabashima K. Alopecia areata: what’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017 [citado 28/10/2021];86(1):3-12. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0923181116308416
6. Welsh O. Phototherapy for alopecia areata. Clin Dermatol. 2016 [citado 11/10/2021];34(5):628-32. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0738081X1630150X
7. Li J, van Vliet C, Rufaut NW, Jones LN, Sinclair RD, Carbone FR. Laser capture microdissection reveals transcriptional abnormalities in alopecia areata before, during, and after active hair loss. J Invest. Dermatol. 2016;136(3):715-8.
8. Torales JC, Malatesta EM, González LL, González IA, López RD, Barrios JI, et al. Psicodermatología: una introducción a sus conceptos, nosología y modelos de abordaje. An Fac Cienc Méd. (Asunción). 2020 [citado 11/10/2021];53(2):127-36. Disponible en: https://observatorio.fm.usp.br/bitstream/OPI/38136/1/art_TORALES_Psicodermatologia_una_introduccion_a_sus_conceptos_nosologia_y_2020.PDF.pdf
9. Fernández Rodríguez JC, Miralles Muñoz F, Millanas Cuevas L. Alopecia areata y personalidad: estado de su relación a través de una revisión bibliográfica. RICS. 2019 [citado 11/10/2021];8(15):19-39. Disponible en: https://www.rics.org.mx/index.php/RICS/article/view/78/303
10. Salazar Nieves M. Calidad de vida en las alopecias e influencia de la relación médico paciente. Alcoy: 3Ciencias; 2017.
11. Ranpariya RH, Gupta SB, Deora MS, Agrawal PV, Mathur R, Raheja A. Intralesional triamcinolone acetonide versus platelet rich plasma: a comparative study in the treatment of alopecia areata of scalp. Int J Res Dermatol. 2019 [citado 11/10/2021];5(3):521-7. Disponible en: https://www.ijord.com/index.php/ijord/article/view/697/379
12. Rodgers AR. Why finding a treatment for alopecia areata is important: a multifaceted perspective. J Invest Dermatol Symposium Proceedings. 2019 [citado 11/10/2021];19(1):51-3. Disponible en: https://www.sciencedirect.com/science/article/pii/S1087002417300412
13. Garcia Melendo C, Cubiró X, Puig L. Janus kinase inhibitors in dermatology: part 1—general considerations and applications in vitiligo and alopecia areata. Actas Dermosifiliogr. 2021 [citado 11/10/2021];112(6):503-15. Disponible en: https://www.sciencedirect.com/science/article/pii/S1578219021001499
14. FIvenson D. COVID‐19: association with rapidly progressive forms of alopecia areata. Int J Dermatol. 2021 [citado 11/10/2021];60(1):127. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753616/pdf/IJD-60-127.pdf
15. Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. J Am Acad Dermatol. 2021 [citado 11/10/2021];85(1):162-75. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0190962220311440
16. Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players. ImmunoTargets Ther. 2021 [citado 11/10/2021];10:299-312. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328385/pdf/itt-10-299.pdf
17. Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clinic Rev Allerg Immunol. 2021;61(3):403-23.
18. Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21:215-30.
19. Senna M, Ko J, Tosti A, Edson Heredia E, Fenske DC, Ellinwood AK, et al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. Adv Ther. 2021 [citado 11/10/2022];38:4646-58. Disponible en: https://link.springer.com/article/10.1007/s12325-021-01845-0
20. Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich SH, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021 [citado 11/10/2022];11:867-83. Disponible en: https://link.springer.com/article/10.1007/s13555-021-00512-0
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
